Interstitial Lung Disease - Pipeline Insight, 2025

DelveInsight’s, Interstitial Lung Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Interstitial Lung Disease Understanding

Interstitial Lung Disease: Overview

Interstitial lung disease (diffused parenchymal diseases) are a heterogeneous group of disorders characterized by fibrosis (scarring) of the lungs. These are classified on the basis of histopathological, radiologic and clinical parameters.

The classification system used to describe interstitial lung disease categorizes conditions based on clinical, histopathological or radiologic parameters. Clinical classification groups ILD by its causes to help differentiate exogenous or endogenous factors. Interstitial lung disease diseases without identifiable causes get grouped under idiopathic/primary which uses the histopathological and radiological approach as its infrastructure. Many of the subsets of the disease are of unknown etiology. Regardless, they all ultimately share the same manner of development. The morphological changes seen histologically result from a sequence of inflammation within the parenchyma, which is the portion of the lung involved in gas exchange (the alveoli, the alveolar ducts, and the bronchioles). This compartment is the habitat to various proteins and pro-fibrotic elements. These proteins, after repeated cycles of activation, give rise to accumulation of connective tissue. The trigger can be a known agent that deposited within the lung tissues. In some cases, the fibrosis arises spontaneously

'Interstitial Lung Disease - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Lung Disease pipeline landscape is provided which includes the disease overview and Interstitial Lung Disease treatment guidelines. The assessment part of the report embraces, in depth Interstitial Lung Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Lung Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Interstitial Lung Disease. The therapies under development are focused on novel approaches to treat/improve Interstitial Lung Disease.

Interstitial Lung Disease Emerging Drugs

DWN12088: Daewoong Pharmaceutical

DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body’s ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein’s sequence. The FDA designated it as an orphan drug for idiopathic pulmonary fibrosis (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.

LYT-100: PureTech

LYT-100 is PureTech's most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.

BMS-986278: Bristol-Myers Squibb

BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation

Interstitial Lung Disease: Therapeutic Assessment

This segment of the report provides insights about the Interstitial Lung Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Interstitial Lung Disease

There are approx. 120+ key companies which are developing the therapies Interstitial Lung Disease. The companies which have their Interstitial Lung Disease drug candidates in the most advanced stage, i.e phase III include Pfizer

Phases

The report covers around 120+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interstitial Lung Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Lung Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Lung Disease drugs.

Interstitial Lung Disease Report Insights

• Interstitial Lung Disease Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Interstitial Lung Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Interstitial Lung Disease drugs?
• How many Interstitial Lung Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Lung Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Interstitial Lung Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Interstitial Lung Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Roche
• aTyr Pharma
• Boehringer Ingelheim
• FibroGen
• LTT Bio-Pharma
• Bristol-Myers Squibb
• Prometheus Biosciences
• HEC Pharm
• Bayer
• Insmed
• Avalyn Pharma
• PureTech Health
• Novartis
• Horizon
• MediciNova
• Endeavor BioMedicines
• Pliant Therapeutics
• Kadmon Pharmaceuticals
• GenKyoTex
• Lung Therapeutics
• AdAlta
• Ark Biosciences

Key Products

• RO-0220912
• ATYR1923
• BI 1015550
• Pamrevlumab
• Zinpentraxin alfa
• LT 0011
• Abatacept
• PRA023
• Yifenidone
• Riociguat
• Treprostinil Palmitil
• BMS 986278
• Pirfenidone inhalation
• Deupirfenidone
• Ianalumab
• HZN-825
• Tipelukast
• ENV-101
• PLN-74809
• KD025
• Setanaxib
• LTI-03
• AD-214
• AK 3280

This product will be delivered within 1-3 business days.